OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance

What happened

OrthoPediatrics reported record third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier. Domestic revenue rose 19% and international revenue rose 18%. The company also raised its 2026 financial guidance.

Confirmed

Global impact / market context

Faster revenue growth means the company sells more pediatric orthopedic products, which can improve profit per sale and cash available to reinvest. Higher guidance signals management expects the trend to continue, which matters to investors valuing future earnings.

Analyst inference

Medical device companies grow by winning surgeon adoption and adding new products. OrthoPediatrics also reported record adjusted EBITDA of $6.9 million, a common measure of operating profit, and positive free cash flow, suggesting spending and operations are moving toward self-funding.

Analyst inference

What to watch

1. Watch whether the raised 2026 guidance is met, since the company increased its full-year outlook alongside these third-quarter results. Confirmed
2. Track adoption of newly released products, including the 3P Pediatric Plating Platform Hip System, because new products can add revenue and support growth. Analyst inference
3. Monitor free cash flow and adjusted EBITDA in coming quarters to see whether higher sales convert into cash rather than being absorbed by costs. Proposed

Evidence

• globenewswire.com